📊 NUWE Key Takeaways
Is NUWE a Good Investment? Thesis Analysis
Nuwellis exhibits severe financial distress with persistent operating losses, negative margins across all profitability metrics, and deteriorating cash burn. The company is losing $2.11 on every dollar of revenue while burning through ~$10.9M in free cash flow annually, creating an unsustainable business model with limited runway given only $1.1M in cash reserves.
Why Buy NUWE? Key Strengths
- Gross margin of 62% demonstrates viable underlying product economics
- Current ratio of 1.71x provides near-term liquidity cushion
- Debt-to-equity of 0.75x is relatively moderate compared to profitability crisis
NUWE Investment Risks to Consider
- Operating losses of -$11.1M dwarf $8.3M revenue, indicating fundamental business model failure
- Negative free cash flow of -$10.9M with only $1.1M cash creates acute solvency risk
- ROE of -667.7% and ROA of -286.4% indicate shareholder capital is being destroyed at accelerating rates
- Interest coverage of -22.0x shows inability to service debt from operations
- Revenue declining 5.4% YoY while losses expand, indicating market rejection and scaling problems
Key Metrics to Watch
- Quarterly cash burn rate and months of runway remaining
- Path to operating cash flow breakeven or evidence of strategic restructuring
- Revenue stabilization or return to growth with margin improvement
NUWE Financial Metrics
💡 AI Analyst Insight
Nuwellis, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
NUWE Profitability Ratios
NUWE vs Healthcare Sector
How Nuwellis, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NUWE Overvalued or Undervalued?
Based on fundamental analysis, Nuwellis, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NUWE Balance Sheet & Liquidity
NUWE 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Nuwellis, Inc.'s revenue has grown significantly by 10% over the 5-year period, indicating strong business expansion. The most recent EPS of $-353.30 indicates the company is currently unprofitable.
NUWE Growth Metrics (YoY)
NUWE Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.2M | $468.0K | $0.56 |
| Q2 2025 | $1.7M | -$3.0M | $-60.99 |
| Q1 2025 | $1.9M | -$3.0M | $-0.69 |
| Q3 2024 | $2.4M | $2.4M | $1.74 |
| Q2 2024 | $2.1M | -$4.3M | $-18.85 |
| Q1 2024 | $1.8M | -$4.3M | $-0.60 |
| Q3 2023 | $2.1M | -$3.4M | $-1.81 |
| Q2 2023 | $2.1M | -$4.3M | $-3.65 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NUWE Capital Allocation
NUWE SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Nuwellis, Inc. (CIK: 0001506492)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NUWE
What is the AI rating for NUWE?
Nuwellis, Inc. (NUWE) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NUWE's key strengths?
Claude: Gross margin of 62% demonstrates viable underlying product economics. Current ratio of 1.71x provides near-term liquidity cushion.
What are the risks of investing in NUWE?
Claude: Operating losses of -$11.1M dwarf $8.3M revenue, indicating fundamental business model failure. Negative free cash flow of -$10.9M with only $1.1M cash creates acute solvency risk.
What is NUWE's revenue and growth?
Nuwellis, Inc. reported revenue of $8.3M.
Does NUWE pay dividends?
Nuwellis, Inc. does not currently pay dividends.
Where can I find NUWE SEC filings?
Official SEC filings for Nuwellis, Inc. (CIK: 0001506492) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NUWE's EPS?
Nuwellis, Inc. has a diluted EPS of $-25.39.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NUWE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Nuwellis, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NUWE stock overvalued or undervalued?
Valuation metrics for NUWE: ROE of -667.7% (sector avg: 15%), net margin of -211.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NUWE stock in 2026?
Our dual AI analysis gives Nuwellis, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NUWE's free cash flow?
Nuwellis, Inc.'s operating cash flow is $-10.8M, with capital expenditures of $90.0K. FCF margin is -131.8%.
How does NUWE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -211.9% (avg: 12%), ROE -667.7% (avg: 15%), current ratio 1.71 (avg: 2).